For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
This study will test a different treatment option for patients with peripheral T-cell lymphoma. The purpose of this study is to compare the usual chemotherapy alone to using high dose chemotherapy followed by a transplant of your own stem cells after completing the usual chemotherapy.
The purpose of this study is to compare the usual treatment for FLT3 mutated acute myeloid leukemia (AML) with a new drug that has two different treatment schedules.
This trial is part of a larger platform study called myeloMATCH – https://www.ctg.queensu.ca/patients/hematology-clinical-trial-alc7.
The purpose of this study is to compare the usual treatment for high-risk acute myeloid leukemia (AML) with four different combinations of treatment.
This trial is part of a larger research study called myeloMATCH which uses biomarker testing to match people to a clinical trial for AML treatment. Find out more >
The purpose of this study is to compare the usual treatment for acute myeloid leukemia (AML) with two different combinations of treatment.
This trial is part of a larger platform study called myeloMATCH > Find out more.
The purpose of this study is to find out if the addition of a new oral drug to the usual treatment will lower the chance of your primary central nervous system lymphoma (PCNSL) growing or spreading.
This trial is the first step in joining a large research study called myeloMATCH.
The purpose of this study is to see the effects on you and your lymphoma of a new drug combination compared to other drugs that are currently used in standard treatment.
Treatment for multiple myeloma sometimes involves three or four medicines. One of these medicines may be stopped after a few months. The others are continued indefinitely until they stop working, or side effects happen. In this study, we are testing if the injection can be stopped after around 18 months of treatment with no change to how your multiple myeloma is being controlled.
The purpose of this study is to compare the usual treatment for your Hodgkin lymphoma, which is a standard combination of four drugs, versus the standard combination with one drug of the combination replaced with a new drug that we hope will be more effective and cause you fewer side effects.
The purpose of this study is to help researchers to better understand the effect of giving two oral medications in patients with mantle cell lymphoma (MCL) who are planning to receive standard of care CAR-T cell therapy.
This study will help researchers to better understand if these two medications make things better or worse than the usual approach alone (CAR-T cell therapy).
